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Short Communication
Effect of Atrial Natriuretic Factor on Skin 
Microcirculation Versus Skeletal Muscle Blood Flow
A. J. W. Branten, P. Smits, T. L. Th. A. Jansen, H. Wollersheim, and Th. Thien
Departments o f Medicine and Pharmacology, University Hospital Nijmegen, Nijmegen, The Netherlands
Summary: The response of the skin microcirculation and 
of forearm skeletal muscle blood flow to infusion of a-hu- 
man (99-126) atrial natriuretic factor (ANF) into the bra­
chial artery was investigated in 15 young (18-25 years) 
healthy volunteers in a double-blind, randomized, pla­
cebo-controlled study. The forearm blood flow (FBF) 
was measured with venous occlusion plethysmography, 
and the skin flux was measured by using laser Doppler 
fluxmetry (LDF). Dose-response curves were made us­
ing increasing dosages of ANF: 1, 10, and 100 ng/min/dl 
forearm volume. The FBF showed a significant, dose- 
dependent increase during ANF infusion, averaging 107 
+ 22% during the highest ANF dosage, as compared with 
— 5 ± 9% during placebo (p < 0.001). For the LDF, these
numbers were 34 ± 21 and —6 ± 10%, respectively (NS). 
In two subgroups of subjects, the effect of ANF on mi­
cro vascular reactivity was assessed by registering the 
vasoconstrictor response to cold exposure (n = 7) and 
the vasodilator response to arterial occlusion (n = 7). 
ANF did not change the microvascular response to these 1 
stimuli. ANF induces a dose-dependent increase in skel­
etal muscle BF without a relevant response in the skin 
microcirculation. ANF does not play an important role in 
the regulation of skin perfusion. Key Words: 8-Human (99- 
126) atrial natriuretic factor—Skin microcirculation— 
Laser Doppler flux—Forearm blood flow—Plethysmog­
raphy .
The hormonal system of atrial natriuretic factor 
(ANF) comprises a family of polypeptides of which 
the 28-amino acid (99~126)-human ANF is the major 
circulating form (1). ANF is considered to contrib­
ute essentially to the control of circulatory homeo­
stasis in physiological as well as in pathophysiolog­
ical conditions (2,3). ANF exerts important effects 
on the renin-angiotensin system and (p a ra s y m ­
pathetic nervous system, in addition to having di­
rect vasodilator and renal actions (4,5). The marked 
vasodilator effects in vitro and in normal subjects 
have been described especially in large vessels 
(6,7). Some studies show controversial results of 
the vasodilator effect of ANF; e.g., data suggest 
that ANF may cause selective vasodilation of the 
kidney (8), contrary to data indicating no alteration 
in renal blood flow (9). A N F has been demonstrated
to increase dose dependently both skin perfusion 
and muscle blood flow (BF). In these particular 
studies, A N F was adm inistered intravenously in 
high dosages (10), and intraarterially by infusion of 
supraphysiological (pharmacological) dosages (11). 
Previously we demonstrated that the systemic A N F 
administration evokes a  slight vasodilation in the 
skin microcirculation of healthy elderly humans 
(12). We have now studied the effect of exogenous 
ANF on skin BF as indicated by laser Doppler flux 
(LDF: capillary and shunt BF in the skin) versus the 
effects of A N F on the skeletal muscle forearm BF 
(FBF) indicated by venous occlusion strain-gauge 
plethysmography. Because in vitro studies in rats 
have shown that A N F reverses a-adrenocep to r- 
mediated vasoconstriction (13), we also investigate 
ed the effect of ANF on microvascular reactivity.
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SUBJECTS AND METHOD
The study was approved by the local ethics committee. 
A group of healthy young volunteers (n = 15), recruited 
from the general population was submitted to clinical ex­
amination before admission to the study. Physical exam­
ination and laboratory investigation showed no abnormal­
ities. None of the subjects used any drugs (oral contra­
ceptives included) or abused alcohol. The subjects were 
instructed to abstain from smoking and not to drink any 
coffee or tea for 24 h preceding the experiment.
Study design
The study was performed during a 4-h immobilization 
period in a climatized room (temperature ± SD: 22.6° ± 
0.2°C; n = 15). The subjects were allowed to eat a light 
meal, but not within 2 h before the test. The tests were 
performed after an equilibration period of at least 45 min 
with the subjects in the supine position.
The left brachial artery was cannulated with a 20-gauge 
Angiocath cannula (Deseret Medical, Becton Dickinson, 
Sandy, U.S.A. UT, U.S.A.) for drug infusion (automatic 
syringe infusion pump, type STC-521, Terumo, Tokyo, 
Japan) as well as for blood pressure (BP) monitoring 
(Hewlett Packard monitor, type 78353B, Hewlett Packard 
GmbH, Böblingen, Germany). Because the dosages of all 
drugs were calculated per deciliter of forearm volume, 
this volume was measured in all participants by water 
displacement. The subjects remained supine throughout 
the 4-h study period.
During the study, systolic and diastolic BP (SBP, DBP) 
and mean arterial pressure (MAP) were recorded intra 
arterially. Heart rate (HR) was monitored continuously 
by ECG registration. FBF was measured by venous oc­
clusion plethysmography with mercury-in-rubber strain 
gauges (Loosco BVP 96 Hoekloos, Amsterdam, Hol­
land). A cuff was placed around the left arm, proximal to 
the strain gauge. Venous occlusion was attained by infla­
tion of the cuff to 40 mmHg. Each FBF recording period 
took 4 min, during which time nine recordings were ob­
tained. During the measurements, the left arm was main­
tained at heart level (14). Digital skin blood flux was re­
corded continuously with laser Doppler fluxmetry (Peri- 
flux Pf Id, Perimed, Sweden). The laser light penetrates 
to a maximum depth of 1.5 mm depending on skin com­
position. The Doppler flux reflects skin microcirculation, 
including nutritional capillaries and arteriovenous shunt 
flow (15,16), The flux was expressed in perfusion units 
(PU). To the center of the left distal palmar tip of the third 
finger, a 90° angular probe was attached by a double-sided 
adhesive ring. Before each experiment, an electrical cal­
ibration procedure was performed according to the man­
ual; i.e., the probe was placed in a calibration clip on zero 
surface, and the recorder pen was moved to zero on the 
recorder. To correct flux registration for spontaneous va- 
somotion, biological zeroing was performed during total 
occlusion of the finger circulation for 5 min. Skin temper­
ature was measured in degrees Centigrade (Thermocou­
ple, Ellab Instruments, Denmark) with the probe attached 
to the palmar side of the middle phalanx on the third 
finger. All parameters were measured during the several 
infusions of the study.
ANF or placebo was infused into the brachial artery in 
random order. Three increasing dose steps were admin­
istered: 1, 10, and 100 |ULg/min/dl forearm tissue for 10 min
per dose. To evaluate the effect of ANF/placebo on the 
microvascular reactivity, the highest dose of ANF or pla­
cebo infusion was continued to perform a finger cooling 
test in a subgroup of 7 subjects or a post occlusive reac­
tive hyperaemia test in 7 other subjects. In the finger 
cooling test, finger skin temperature and LDF were mea­
sured during a 25-min period, beginning with a 5-min 
cooling procedure in water of 15°C, as described previ­
ously (17). The postocclusive reactive hyperemia test was 
performed by inflating a finger cuff to 230 mm Hg for 5 
min (18). After the cuff was released, the LDF was reg­
istered for 10 min. After a new equilibration period of 45 
min, the same procedure was repeated, but with infusion 
of the alternate agent, placebo or ANF.
Drugs
a-Human (99-126) ANF was purchased from Bissen- 
dorf Peptide GmbH, Wedemark, Germany. Immediately 
before use, ANF was diluted in a 48-ml Haemaccel (Ho- 
echst) solution. Haemaccel is a plasma-expanding solu­
tion and was used for placebo infusion, as well as for 
dissolving ANF, Results of pilot studies showed that dis­
solving iodinated ANF in Haemaccel solution resulted in 
a 20% loss of radioactivity to the infusion system as com­
pared with a 50% loss when ANF was dissolved in 0.9% 
in saline solution, as we reported previously (12).
Data
All results are mean ± SEM unless indicated other­
wise. LDF was averaged over the last 5 min of each ANF 
infusion dosage. FBF was calculated as the mean of all 
registration during the last 4 min of each dose.
Statistical analysis
To determine the effects of ANF infusion within each 
group of subjects, we compared the absolute as well as 
percentage ANF-induced changes with corresponding 
placebo observations for each infusion rate by analysis of 
variance (ANOVA) with repeated measures. In case of a 
significant ANF effect, Fisher PLSD tests (protected 
least significant difference) were used as post hoc tests to 
analyze the differences between baseline and the several 
ANF dosages and also for the analysis of the finger cool­
ing tests and the postocclusive reactive hyperemia tests. 
Differences were considered statistically significant at p
< 0.05.
RESULTS
In all, 9 males and 6 females participated in the 
study. Their mean (±SD) age, body mass index, 
SDB/DBP, and HR was 25 ± 4 years, 22 ± 2 kg/m2, 
125 ± 6/73 ± 6 mm Hg, and 74 ± 12 beats/min, 
respectively. The serum creatinine concentrations 
averaged 72 ± 9 \lM>
Effects of ANF on baseline parameters (n = 15) \
Figure 1 shows the absolute changes from base­
line induced by graded infusion of ANF or placebo 
for the FBF as well as for the LDF. The baseline 
FBF was 2.1 ± 0.3 ml/min/dl in both the placebo 
and the ANF test. Corrected for the changes in­
duced by placebo, the FBF increased 0.2 ± 0.3 dur­
ing the lowest, 0.8 ± 0.3 during the middle, and 2.1
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FIG. 1. Mean (±SE) changes from baseline of the forearm 
blood flow (AFBF) and the laser Doppler flux (ALDF) as in­
duced by Infusion of three increasing dosages of atria! natri­
uretic factor (ANF, solid squares/solid lines) or placebo (open 
diamonds/dashed lines). Indicated p-values refer to the com­
parison between ANF- and placebo-induced changes, as­
sessed by repeated-measures analysis of variance. *Post hoc 
testing by Fisher protected least significant difference 
(PLSD) on placebo-corrected effect of ANF; p < 0.05 versus 
baseline.
± 0.4 ml/min/dl during the highest ANF dose (p < 
0.001). Table 1 summarizes the percentage changes 
from baseline after ANF and after placebo and also 
shows a dose-dependent increase in FBF after ANF 
as compared with placebo.
The baseline LDF averaged 10.7 ± 2.6 PU in the 
placebo test and 8.5 ± 2.2 PU in the ANF test. This 
parameter increased slightly, though significantly, 
after the three ANF infusions (placebo-corrected
changes: 1.4 ±  1.3, 3.3 ±  2.2, and 4.2 ±  2.0 PU, p 
< 0.05). As shown in Table 1, the ANF-induced 
percentage changes from baseline were slight and 
not significantly different from those induced by 
placebo.
Effect of ANF on mlcrovascular reactivity
In the placebo series, cold exposure to the fingers 
did not change the FBF (1.7 ± 0.1 at baseline and 
1.6 ± 0.1 immediately after cold exposure, n = 7). 
However, during the procedure, LDF decreased 
from 9.9 ±  2,3 to 6.1 ±  2.0 PU. In the recovery 
phase, the LDF gradually increased to 7,0 ± 3 . 7  PU 
after 25 min. For the skin temperature, these values 
averaged 29.0° ± 0.5°C at baseline, 21.2° ±  0.5°C 
immediately after cold exposure, and 23.1° ± 1.6°C 
after 25 min of recovery. Although the highest dose 
of ANF increased the baseline values of FBF and 
LDF, the course of these parameters after cold ex­
posure was not changed by ANF as compared with 
placebo.
In the placebo series, the peak response of the 
LDF after occlusion of the finger was 21.1 ± 2 . 9  PU 
and reached 48.3 ±  13.4 PU seconds after the end of 
occlusion (n = 7). The LDF returned toward base­
line level in 243.5 ±  36.3 s. In the presence of ANF, 
these values were comparable (peak response 21.6 
±4.3 PU reached after 67.2 ±  18.0 s; recovery time 
305.0 ± 62.3 s).
DISCUSSION
We demonstrated that infusion of ANF into the 
brachial artery induced a significant dose-depen­
dent increase in FBF but only a slight increase in 
skin flux in healthy subjects. Plethysmographic 
FBF measurement includes both skeletal muscle 
BF and skin BF. The increase in FBF was more 
pronounced than the changes in skin flux. There­
fore, the changes in the plethysmography values in 
this study must be attributed mainly to increases in 
skeletal muscle BF. The magnitude of the effects on 
skin microcirculation was remarkably small and ap­
peared to occur only at the highest dose o f ANF. 
We observed large differences between control val­
ues of LDF before ANF and placebo infusion. Be­
cause the sequence of testing was randomized, a 
time effect cannot explain this difference in baseline
TABLE 1. Mean (±SE) percentage changes from baseline for  the HlFBF and the bJLDF during the three dosages o f
ANF and placebo
Parameter Placebo 1 Placebo 2 Placebo 3 ANF-1 ANF-2 ANF-3
AFBF {%)a 9 ±  10 5 ± 8 - 5  ± 9 4 ± 3 37 ±  9b 107 ±  22*
ALDF (%) (NS)C 1 ±  7 2 ±  10 — 6 ± 10 2 ±  5 11 ±  8 34 ±  21
FBF, forearm blood flow; LDF, laser Doppler flux; ANOVA, analysis of variance; ANF, atrial natriuretic factor. 
°p = 0.0001 repeated-measures ANOVA for ANF versus placebo.
*Post hoc testing by Fisher PLSD on placebo-corrected effect of ANF: p <  0.05 versus baseline. 
cNo significant difference by repeated-measures ANOVA.
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level. Large differences in LD F were observed and 
described previously. Despite this variability, LDF 
is considered useful in measuring skin microcircu- 
latory reactivity during interventions (17,19). Previ­
ous studies in our departm ent have shown that the 
regional A N F concentrations reached at the highest 
dose are much higher than in (patho)physiological 
conditions (20). By dividing the A N F infusion rate 
by the forearm plasma flow (FBF x [l-hematocrit])5 
the regional plasma A N F concentrations during the 
lowest dose of 1 ng/min/dl can be estimated as ~1 
ng/ml, w hereas physiological concentrations are 
generally <0.1 ng/ml. Therefore, our results indi­
cate that only supraphysiological levels of ANF in­
duce a slight vasodilator response in the microcir­
culation.
Contradictory reports on the microcirculatory ef­
ficacy of A N F  have been  published previously 
(10,11). In a previous study, using the intravenous 
route of A N F adm inistration, we reported that 
A N F was not a potent vasodilator in the skin mi­
crocirculation. H ow ever, systemic administration 
of A N F is complicated by cardiovascular reflex ac­
tivity compensating for induced effects. Therefore, 
in the present study, we used the regional route of 
A N F administration to rule out the influence of 
com pensatory m echanism s. Our current results 
suggest that A N F plays only a minor direct vasodi­
lator role in normal skin microcirculation, in con­
trast to a more pronounced vasodilator effect on 
skeletal muscle BF.
We further investigated possible modulatory ef­
fects of A N F on the a-adrenoceptor-m ediated mi­
crocirculatory constrictor response to finger cool­
ing. The postsynap tic  a-adrenoceptor-m ediated  
vasoconstrictor response to cold exposure in hu­
man skin microcirculation is believed to be predom­
inantly mediated by the a 2-subtype (21). In vivo 
studies with selective a r  and a 2-agonists have sup­
ported the concept of heterogeneity of postjunc­
tional a-adrenoceptors in human vasculature. Faber 
and colleagues demonstrated that A N F was highly 
potent in selectively reversing a r adrenoceptor- 
mediated constriction (13), but in their study a 2- 
adrenoceptor-m ediated constriction was ANF in­
sensitive, which may explain the absence of an ef­
fect of A N F on cold-induced vasoconstriction in 
our study. Our experiments with postocclusive re­
active hyperem ia indicate that A N F apparently 
does not modulate microvascular vasodilator func­
tion.
A N F induces a direct dose-dependent vasodilator 
effect on the skeletal muscle vascular bed. In sup­
raphysiological concentrations, A N F can also dilate 
the skin microcirculation, but does not appear to 
change microvascular reactivity.
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